FDA 483 - Continental Services Group, Inc. - August 24, 2022

An FDA inspection of Continental Services Group, Inc., a blood bank and plasma center in Ft Lauderdale, revealed two significant observations. The firm failed to maintain adequate donor and general records, specifically regarding software validation for donor screening. Additionally, the inspection found that the firm did not make reasonable attempts to notify donors of positive HIV and HCV test results within the required timeframe.